Shyld Funding: How Much Did They Raise & Key Investors

How Much Did Shyld Raise?
Funding & Key Investors

Shyld has successfully secured a significant capital injection, marking a pivotal moment in its corporate trajectory. With a total funding accumulation of $13.4M, the company is well-positioned to scale its autonomous AI-powered systems for clinical environments. This latest financing round, which contributed $13.4M to the firm's balance sheet, underscores strong investor confidence in the company's ability to integrate edge AI and UV-C disinfection technology into the modern hospital infrastructure.

The infusion of capital serves as a strategic catalyst for Shyld, enabling the firm to accelerate its product development roadmap and expand its footprint within the healthcare technology sector. By leveraging this recent investment, Shyld aims to solidify its market position as a leader in operational efficiency and infection control, addressing critical pain points in patient safety and clinical workflow management.

What is Shyld?

Shyld

Software

Healthcare Software

Manufacturing

Shyld operates at the intersection of healthcare technology and artificial intelligence, providing autonomous systems designed to optimize hospital operations. The company's platform utilizes a sophisticated combination of edge AI, multimodal sensing, and workflow intelligence to automate complex clinical processes. By integrating UV-C disinfection technology directly into the hospital environment, Shyld effectively reduces manual intervention, enhances compliance management, and improves overall environmental sanitization. This comprehensive approach allows healthcare facilities to achieve real-time decision-making capabilities, ultimately fostering a safer and more efficient clinical ecosystem.

How much funding has Shyld raised?

Shyld has raised a total of $13.4M across 1 funding round:

2026

Seed

$13.4M

Seed (2026): $13.4M with participation from Aulis Capital

Key Investors in Shyld

Aulis Capital

Aulis Capital is a Palo Alto-based venture firm specializing in early and growth-stage healthcare investments, led by industry veteran Nisa Leung. The firm leverages deep scientific and analytical expertise to accelerate medical technology innovations that improve patient outcomes.

What's next for Shyld?

Looking ahead, Shyld is poised to leverage its recent capital influx to transition from its current development phase toward broader commercial deployment. The company's strategic focus will likely center on scaling its autonomous monitoring and disinfection solutions across diverse clinical settings, thereby enhancing its value proposition for large-scale hospital networks. As the healthcare industry continues to prioritize digital transformation and infection prevention, Shyld's ability to provide actionable workflow intelligence will be a key differentiator. Future growth will depend on the successful integration of its proprietary technology into existing hospital IT infrastructures and the continued expansion of its operational footprint in both domestic and international markets.

See full Shyld company page

See More Financial Insights